[go: up one dir, main page]

UY28182A1 - Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular - Google Patents

Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular

Info

Publication number
UY28182A1
UY28182A1 UY28182A UY28182A UY28182A1 UY 28182 A1 UY28182 A1 UY 28182A1 UY 28182 A UY28182 A UY 28182A UY 28182 A UY28182 A UY 28182A UY 28182 A1 UY28182 A1 UY 28182A1
Authority
UY
Uruguay
Prior art keywords
antagonist
combination
acid
angiotensin
acetilsalicyl
Prior art date
Application number
UY28182A
Other languages
English (en)
Inventor
James C Gilbert
Lutz Hilbrich
Axel Riedel
David Michael Humphreys
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY28182A1 publication Critical patent/UY28182A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a un método para prevenir el accidente cerebrovascular o para reducir el riesgo de accidente cerebrovascular en un paciente que requiere tratamiento, especialmente en un paciente de riesgo para un accidente cerebrovascular o para un accidente cerebrovascular secundario, usando dipiridamol en combinación con ácido acetilsalicílico (ASA) y un antagonista de angiotenasina II, composiciones farmacéuticas correspondientes, y al uso de dipiridamol para la fabricación de una composición farmacéutica correspondiente que comprende una combinación de dipiridamol, ácido acetilisalicílico y un antagonista de angiotensina II.
UY28182A 2003-02-13 2004-02-10 Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular UY28182A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10306179A DE10306179A1 (de) 2003-02-13 2003-02-13 Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP03018212 2003-08-08

Publications (1)

Publication Number Publication Date
UY28182A1 true UY28182A1 (es) 2004-09-30

Family

ID=32870338

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28182A UY28182A1 (es) 2003-02-13 2004-02-10 Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular

Country Status (29)

Country Link
US (5) US20040214802A1 (es)
EP (2) EP1603573B8 (es)
JP (1) JP2006517557A (es)
KR (1) KR20050100676A (es)
CN (1) CN1750830A (es)
AR (1) AR043173A1 (es)
AT (1) ATE395921T1 (es)
AU (1) AU2004212305A1 (es)
BR (1) BRPI0407457A (es)
CA (1) CA2515941A1 (es)
DE (2) DE10306179A1 (es)
DK (1) DK1603573T3 (es)
EA (1) EA200501231A1 (es)
EC (1) ECSP055963A (es)
ES (1) ES2308147T3 (es)
HR (1) HRP20050713A2 (es)
MX (1) MXPA05008572A (es)
NO (1) NO20054216D0 (es)
NZ (1) NZ542302A (es)
PE (1) PE20050191A1 (es)
PL (1) PL378204A1 (es)
PT (1) PT1603573E (es)
RS (1) RS20050618A (es)
SI (1) SI1603573T1 (es)
TW (1) TW200501957A (es)
UA (1) UA83481C2 (es)
UY (1) UY28182A1 (es)
WO (1) WO2004071385A2 (es)
ZA (1) ZA200505956B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
CA2437709A1 (en) * 2003-08-08 2005-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
JP2005060359A (ja) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
EP3250201A4 (en) * 2015-01-28 2018-08-01 Realinn Life Science Limited Compounds for enhancing ppar expression and nuclear translocation and therapeutic use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3317279A (en) * 1963-03-15 1967-05-02 Pennsalt Chemicals Corp Polymorph of calcium disilicide and its method of preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
EP1013273A1 (en) 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
JP2002138054A (ja) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd フィブリノーゲン低下剤
JP2002293742A (ja) * 2001-01-29 2002-10-09 Takeda Chem Ind Ltd 鎮痛・抗炎症剤
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe

Also Published As

Publication number Publication date
CA2515941A1 (en) 2004-08-26
AR043173A1 (es) 2005-07-20
EP1603573B8 (en) 2009-04-01
CN1750830A (zh) 2006-03-22
DK1603573T3 (da) 2008-09-15
BRPI0407457A (pt) 2006-01-31
ZA200505956B (en) 2006-03-29
TW200501957A (en) 2005-01-16
US20080113949A1 (en) 2008-05-15
PL378204A1 (pl) 2006-03-20
PT1603573E (pt) 2008-06-26
EP1603573B1 (en) 2008-05-21
ES2308147T3 (es) 2008-12-01
ECSP055963A (es) 2006-01-16
EP1603573A2 (en) 2005-12-14
EP1733729A1 (en) 2006-12-20
UA83481C2 (uk) 2008-07-25
US20080188497A1 (en) 2008-08-07
WO2004071385A2 (en) 2004-08-26
NZ542302A (en) 2008-12-24
AU2004212305A1 (en) 2004-08-26
NO20054216L (no) 2005-09-12
WO2004071385A3 (en) 2005-01-06
PE20050191A1 (es) 2005-04-12
MXPA05008572A (es) 2005-11-04
RS20050618A (sr) 2007-09-21
JP2006517557A (ja) 2006-07-27
US20070004687A1 (en) 2007-01-04
SI1603573T1 (sl) 2008-10-31
DE10306179A1 (de) 2004-08-26
KR20050100676A (ko) 2005-10-19
EA200501231A1 (ru) 2006-02-24
NO20054216D0 (no) 2005-09-12
US20060241089A1 (en) 2006-10-26
ATE395921T1 (de) 2008-06-15
US20040214802A1 (en) 2004-10-28
HRP20050713A2 (en) 2006-09-30
DE602004013937D1 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
ECSP055525A (es) Inhibidores de cinasas de tirosina
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
CR10091A (es) Compuestos orgánicos
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
CL2007002856A1 (es) Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer.
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
PA8803201A1 (es) Derivados acidos de cicloalquilamino
ECSP12007431A (es) Compuestos orgánicos
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
UY28182A1 (es) Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular
GT200600135A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
CU20070094A7 (es) Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
MX2007007610A (es) Regimen de cladribina para tratar esclerosis multiple.
AR106331A2 (es) N-benzoil-estaurosporina, forma ii
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
BRPI0416906A (pt) proteinúria tubular como um indicador para risco cardiovascular elevado

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140310